<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802201</url>
  </required_header>
  <id_info>
    <org_study_id>PTG-300-02</org_study_id>
    <nct_id>NCT03802201</nct_id>
  </id_info>
  <brief_title>Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia</brief_title>
  <acronym>TRANSCEND</acronym>
  <official_title>A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protagonist Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protagonist Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort&#xD;
      . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence&#xD;
      of efficacy of PTG-300 for the treatment in β-thalassemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort&#xD;
      and with the potential for individual titration (dose increase or decrease) within each&#xD;
      cohort. The study is designed to monitor the PTG-300 safety profile, to obtain preliminary&#xD;
      evidence of efficacy of PTG-300 for the treatment of chronic anemia in β-thalassemia and to&#xD;
      evaluate the appropriate dosing regimen for PTG-300 in the target population&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2018</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Multiple PTG-300 dose levels/regimens are planned to be tested for each subpopulation of β thalassemia (NTD and TD) on separate arms:&#xD;
Cohort 1: 3 mg subcutaneous (SC) weekly&#xD;
Cohort 2: 10 mg SC weekly&#xD;
Cohort 3: 20 mg SC weekly&#xD;
Cohort 4a: 40 mg SC weekly&#xD;
Cohort 4b: 40 mg SC every 2 weeks&#xD;
Cohort 7: 80 mg SC weekly&#xD;
Cohort 8: 40 mg SC twice a week&#xD;
Additional Cohorts (Cohorts 5,6,9,10, and 11) will include subjects between 12 years of age and less than 18 years of age.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NTD: Proportion of responders at each dose</measure>
    <time_frame>4 week period</time_frame>
    <description>NTD subjects who achieve an increase in Hgb without transfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TD: Proportion of clinical responders at each dose</measure>
    <time_frame>8 week period</time_frame>
    <description>TD subjects who achieve a reduction in red blood cell (RBC) units required over an 8 week period</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>β-thalassemia</condition>
  <condition>Ineffective Erythropoiesis</condition>
  <condition>Chronic Anemia</condition>
  <arm_group>
    <arm_group_label>PTG-300 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: PTG-300 Subcutaneous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTG-300</intervention_name>
    <description>Subcutaneous (SC)</description>
    <arm_group_label>PTG-300 Active</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects aged 18 to 65 years, inclusive (Cohorts 1-4b).&#xD;
&#xD;
          2. Male and female subjects aged 12-&lt;18 years, with a minimum weight of 30 kg (Cohorts 5&#xD;
             and 6).&#xD;
&#xD;
          3. Documented diagnosis of β-thalassemia with no other Hgb abnormality.&#xD;
&#xD;
        Inclusion criteria applicable only for NTD β-thalassemia subjects:&#xD;
&#xD;
          1. Mean Hgb &lt; 10.0 g/dL of two measurements (one performed 7-28 days prior to dosing and&#xD;
             the other performed within 7 days prior to dosing).&#xD;
&#xD;
          2. Requirement of &lt; 6 units RBC transfusion in a 24 week period with the last transfusion&#xD;
             at least 8 weeks before screening.&#xD;
&#xD;
        Inclusion criteria applicable only for TD β-thalassemia subjects:&#xD;
&#xD;
          1. Transfusion requirement of at least 6 units of RBC in the 24 weeks prior to screening&#xD;
             with no transfusion free period &gt; 45 days.&#xD;
&#xD;
          2. Last RBC transfusion 5-10 days prior to dosing.&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with Sickle Cell disease, Hgb H, Hb Bart's hydrops foetalis or hemoglobin S&#xD;
&#xD;
          2. Infection requiring hospitalization or IV antimicrobial therapy, or opportunistic&#xD;
             infection within 6 months of dosing, any infection requiring antimicrobial therapy&#xD;
             within 2 weeks of dosing; history of infection with human immunodeficiency virus&#xD;
             (HIV).&#xD;
&#xD;
          3. Subject has a concurrent clinically significant, unstable or uncontrolled&#xD;
             cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary,&#xD;
             hematological, coagulation, immunological, endocrine/metabolic or other medical&#xD;
             disorder that, in the opinion of the Investigator, might confound the results of the&#xD;
             study or pose additional risk to the subject by their participation in the study.&#xD;
&#xD;
          4. Known primary or secondary immunodeficiency.&#xD;
&#xD;
          5. History within 6 months of screening of any of the following:&#xD;
&#xD;
             myocardial infarction, unstable angina, transient ischemic attack, decompensated heart&#xD;
             failure requiring hospitalization, congestive heart failure (New York Heart&#xD;
             Association Class 3 or 4), uncontrolled arrhythmias, cardiac revascularization,&#xD;
             stroke, uncontrolled hypertension (resting systolic blood pressure [BP] &gt; 160mmHg or&#xD;
             resting diastolic BP &gt; 100mmHg on more than one occasion) or uncontrolled diabetes&#xD;
             (Hgb A1c &gt; 9% or &gt; one episode of severe hypoglycemia).&#xD;
&#xD;
          6. Pregnant or lactating females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laiko General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Athens General Hospital 'G Gennimatas'</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU dell'Università degli Studi della Campania Luigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chronic Care Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ampang</name>
      <address>
        <city>Ampang</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>George Town</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultanah Aminah</name>
      <address>
        <city>Johor Bahru</city>
        <zip>80100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Kota Kinabalu</city>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naresuan University</name>
      <address>
        <city>Phitsanulok</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Farhat Hached</name>
      <address>
        <city>Sousse</city>
        <zip>4000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone Marrow Transplant Center</name>
      <address>
        <city>Tunis</city>
        <zip>1006</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aziza Othmana Hospital</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Principal Military Hospital</name>
      <address>
        <city>Tunis</city>
        <zip>1089</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe University Medical Faculty</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akdeniz Universitesi Hastanesi</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tip Fakultesi</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin University Medical Facult</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Thailand</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <disposition_first_submitted>July 9, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 16, 2021</disposition_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic anemia</keyword>
  <keyword>β-thalassemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

